Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions.
Oligodendrogliomas account for a small subset of all gliomas, but they often are more sensitive to treatment than other glioma subtypes. In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic loss of 1p/19q (1p/19q loss), correlates with patient outcome in large-scale prospective clinical trials. However, the incorporation of 1p/19q status into clinical practice remains controversial. Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss.
Ney
Douglas E
DE
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Lassman
Andrew B
AB
D000483:Alleles; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy*; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D019175:DNA Methylation; D066246:ErbB Receptors / Q000378:metabolism; D016158:Genes, p53; D006801:Humans; D009154:Mutation; D009837:Oligodendroglioma / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy*; D010982:Platelet-Derived Growth Factor / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D017479:Receptors, Platelet-Derived Growth Factor / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D010982:Platelet-Derived Growth Factor; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors; D017479:Receptors, Platelet-Derived Growth Factor